(Immuno)proteasomes as therapeutic target in acute leukemia
The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/ https://www.ncbi.nlm.nih.gov/pubmed/29071527 http://dx.doi.org/10.1007/s10555-017-9699-4 |
_version_ | 1783284759505403904 |
---|---|
author | Cloos, Jacqueline Roeten, Margot SF Franke, Niels E van Meerloo, Johan Zweegman, Sonja Kaspers, Gertjan JL Jansen, Gerrit |
author_facet | Cloos, Jacqueline Roeten, Margot SF Franke, Niels E van Meerloo, Johan Zweegman, Sonja Kaspers, Gertjan JL Jansen, Gerrit |
author_sort | Cloos, Jacqueline |
collection | PubMed |
description | The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress. |
format | Online Article Text |
id | pubmed-5721123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-57211232017-12-12 (Immuno)proteasomes as therapeutic target in acute leukemia Cloos, Jacqueline Roeten, Margot SF Franke, Niels E van Meerloo, Johan Zweegman, Sonja Kaspers, Gertjan JL Jansen, Gerrit Cancer Metastasis Rev Article The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress. Springer US 2017-10-25 2017 /pmc/articles/PMC5721123/ /pubmed/29071527 http://dx.doi.org/10.1007/s10555-017-9699-4 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Cloos, Jacqueline Roeten, Margot SF Franke, Niels E van Meerloo, Johan Zweegman, Sonja Kaspers, Gertjan JL Jansen, Gerrit (Immuno)proteasomes as therapeutic target in acute leukemia |
title | (Immuno)proteasomes as therapeutic target in acute leukemia |
title_full | (Immuno)proteasomes as therapeutic target in acute leukemia |
title_fullStr | (Immuno)proteasomes as therapeutic target in acute leukemia |
title_full_unstemmed | (Immuno)proteasomes as therapeutic target in acute leukemia |
title_short | (Immuno)proteasomes as therapeutic target in acute leukemia |
title_sort | (immuno)proteasomes as therapeutic target in acute leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/ https://www.ncbi.nlm.nih.gov/pubmed/29071527 http://dx.doi.org/10.1007/s10555-017-9699-4 |
work_keys_str_mv | AT cloosjacqueline immunoproteasomesastherapeutictargetinacuteleukemia AT roetenmargotsf immunoproteasomesastherapeutictargetinacuteleukemia AT frankenielse immunoproteasomesastherapeutictargetinacuteleukemia AT vanmeerloojohan immunoproteasomesastherapeutictargetinacuteleukemia AT zweegmansonja immunoproteasomesastherapeutictargetinacuteleukemia AT kaspersgertjanjl immunoproteasomesastherapeutictargetinacuteleukemia AT jansengerrit immunoproteasomesastherapeutictargetinacuteleukemia |